Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010 (2010), Article ID 471375, 6 pages
http://dx.doi.org/10.1155/2010/471375
Clinical Study

Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy

1Dattoli Cancer Center & Brachytherapy Research Institute, 2803 Fruitville Rd., Sarasota, FL 34237-5367, USA
2Department of Radiation Oncology and Pathology, University of Washington, Seattle, WA 98195-0001, USA
3Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA 98108-1597, USA
4Group Health Cooperative, Seattle, WA 98124-1590, USA
5Research Division, Bostwick Laboratories, Richmond, VA 23050-4410, USA

Received 28 April 2010; Revised 1 July 2010; Accepted 1 July 2010

Academic Editor: Minesh P. Mehta

Copyright © 2010 Michael Dattoli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Blasko, H. Ragde, and D. Schumacher, “Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance,” Endo/Hypertherm, vol. 3, pp. 131–139, 1987. View at Google Scholar
  2. M. R. Cooperberg, D. P. Lubeck, M. V. Meng, S. S. Mehta, and P. R. Carroll, “The changing face of low-risk prostate cancer: trends in clinical presentation and primary management,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2141–2149, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. O. W. Hakenberg, M. P. Wirth, and M. P. Wirth, “Recommendations for the treatment of localized prostate cancer by permanent interstitial brachytherapy,” Urologia Internationalis, vol. 70, no. 1, pp. 15–20, 2003. View at Google Scholar
  4. T. M. Pisansky, M. L. Blute, and M. L. Blute, “The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma,” Cancer, vol. 95, no. 3, pp. 513–519, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. G. S. Merrick, K. E. Wallner, W. M. Butler, and J. C. Blasko, “Permanent prostate brachytherapy: is supplemental external-beam radiation therapy necessary?” Oncology, vol. 20, no. 5, pp. 514–522, 2006. View at Google Scholar · View at Scopus
  6. M. Dattoli, K. Wallner, L. True, J. Cash, and R. Sorace, “Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features,” Cancer, vol. 110, no. 3, pp. 551–555, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. N. Bittner, G. S. Merrick, K. E. Wallner, and W. M. Butler, “Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer,” Oncology, vol. 22, no. 9, pp. 995–1004, 2008. View at Google Scholar · View at Scopus
  8. M. A. Khan and A. W. Partin, “Partin tables: past and present,” BJU International, vol. 92, no. 1, pp. 7–11, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Febles and R. K. Valicenti, “Combining external beam radiotherapy with prostate brachytherapy: issues and rationale,” Urology, vol. 64, no. 5, pp. 855–861, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. V. D'Amico, R. Whittington, and R. Whittington, “Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer,” Journal of the American Medical Association, vol. 280, no. 11, pp. 969–974, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. D. G. Brachman, T. Thomas, J. Hilbe, and D. C. Beyer, “Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice,” International Journal of Radiation Oncology Biology Physics, vol. 48, no. 1, pp. 111–117, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Dattoli, K. Wallner, and J. Blasko, Prostate Brachytherapy Made Complicated, Smart Medicine Press, Seattle, Wash, USA, 2nd edition, 2001.
  13. J. C. Blasko, P. D. Grimm, J. E. Sylvester, K. R. Badiozamani, D. Hoak, and W. Cavanagh, “Palladium-103 brachytherapy for prostate carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 46, no. 4, pp. 839–850, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. G. S. Merrick, W. M. Butler, K. E. Wallner, R. W. Galbreath, and E. Adamovich, “Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL,” American Journal of Clinical Oncology, vol. 27, no. 6, pp. 611–615, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. G. S. Merrick, W. M. Butler, J. H. Lief, R. W. Galbreath, and E. Adamovich, “Biochemical outcome for hormone-naïve intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation,” Brachytherapy, vol. 1, no. 2, pp. 95–101, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. R. G. Stock, O. Cahlon, J. A. Cesaretti, M. A. Kollmeier, and N. N. Stone, “Combined modality treatment in the management of high-risk prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 59, no. 5, pp. 1352–1359, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. A. V. Roy, M. E. Brower, and J. E. Hayden, “Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum,” Clinical Chemistry, vol. 17, pp. 1093–1102, 1971. View at Google Scholar
  18. M. Dattoli, K. Wallner, and K. Wallner, “Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 45, no. 4, pp. 853–856, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. M. J. Dattoli, K. Wallner, R. Sorace, and J. Ting, “Planned extracapsular seed placement using palladium-103 for prostate brachytherapy,” Journal of Brachytherapy International, vol. 16, no. 1, pp. 35–43, 2000. View at Google Scholar · View at Scopus
  20. R. G. Stock, T. J. Klein, J. A. Cesaretti, and N. N. Stone, “Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 3, pp. 753–758, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. S. L. Liauw, R. R. Weichselbaum, C. Rash, D. Correa, H.A. Al-Hallaq, C. A. Pelizzari, and A. B. Jani, “Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer,” Technology in Cancer Research & Treatment, vol. 8, no. 3, pp. 201–206, 2009. View at Google Scholar · View at Scopus
  22. G. S. Merrick, W. M. Butler, K. E. Wallner, L. R. Burden, and J. E. Dougherty, “Extracapsular radiation dose distribution after permanent prostate brachytherapy,” American Journal of Clinical Oncology, vol. 26, no. 5, pp. 178–189, 2003. View at Google Scholar · View at Scopus
  23. F. A. Critz, “Summary of simultaneous irradiation for prostate cancer,” Urology, vol. 64, no. 4, pp. 633–636, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. D. C. Beyer, T. McKeough, and T. Thomas, “Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 5, pp. 1299–1306, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. R. G. Stock, S. Yamalachi, S. J. Hall, and N. N. Stone, “Impact of hormonal therapy on intermediate risk prostate cancer patients treated with combination brachytherapy and external beam irradiation,” Journal of Urology, vol. 183, no. 2, pp. 546–551, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. J. Andrews and M. Roach III, “Integrating hormonal therapy with external-beam radiation and brachytherapy for prostate cancer,” Oncology, vol. 19, no. 1, pp. 29–36, 2005. View at Google Scholar · View at Scopus
  27. G. S. Merrick, “The role of hormonal therapy in prostate brachytherapy,” Brachytherapy, vol. 2, no. 1, pp. 2–4, 2003. View at Google Scholar · View at Scopus
  28. A. V. D'Amico, J. Manola, M. Loffredo, A. A. Renshaw, A. DellaCroce, and P. W. Kantoff, “6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial,” Journal of the American Medical Association, vol. 292, no. 7, pp. 821–827, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. W. Denham, A. Steigler, and A. Steigler, “Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial,” The Lancet Oncology, vol. 6, no. 11, pp. 841–850, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. M. Bolla, L. Collette, and L. Collette, “Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial,” The Lancet, vol. 360, no. 9327, pp. 103–108, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. D. A. Kuban, L. B. Levy, and L. B. Levy, “Comparison of biochemical failure definitions for permanent prostate brachytherapy,” International Journal of Radiation Oncology Biology Physics, vol. 65, no. 5, pp. 1487–1493, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. G. E. Hanks, T. F. Pajak, and T. F. Pajak, “Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 1992–2002,” Journal of Clinical Oncology, vol. 21, no. 21, pp. 3972–3978, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. V. Ganswindt, “Optimized coverage of high risk adjuvant Lymph Node areas in prostate cancer using a sentinel node based intensity modulated radiation therapy technique,” International Journal of Radiation Oncology Biology Physics, vol. 66, pp. 647–653, 2006. View at Google Scholar
  34. O. Yossepowitch, S. E. Eggener, F. J. Bianco Jr., B. S. Carver, A. Serio, P. T. Scardino, and J. A. Eastham, “Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods,” Journal of Urology, vol. 178, no. 2, pp. 493–499, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. M. Dattoli, “External beam irradiation combined with palladium-103 brachytherapy for high-risk, localized prostatic carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 35, pp. 875–879, 1996. View at Google Scholar